AR092 / Y-Biologics - LARVOL DELTA

AR092, a proprietary HLA-G/CD3 T cell engager, induces anti-tumor activity and minimal toxicity in solid tumors (SITC 2024) - "Finally, AR092 exhibited anti-tumor activity in a 4T1/hB2M-hHLA-G breast tumor syngeneic mouse model, in a A375/hB2M-hHLA-G melanoma CD34+ huHSC-NCG CDX mouse model, and in a 148T ColvM colon tumor PDX mouse model. Conclusions AR092 demonstrated significant antitumor effects in vitro and in vivo and may overcome the limitations of existing immunotherapy treatments by increasing the therapeutic potential and mitigating toxicities."

Breast Cancer • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor • CD34 • HLA-G • IFNG • IL2 • IL6 • LILRB1 • PD-1 • TNFA

Wybiologics presents research results related to tumor microenvironment at the American Society for Immuno-Oncology [Google translation] (BioTimes) - "Antibody drug development platform company Y-Biologics...announced on the 7th that two research results presentations (posters) on pipelines related to the tumor microenvironment, including AR148, were accepted at the Society for Immunotherapy of Cancer 2024 (SITC) in the United States....Wybiologics announces the release of ‘TGFβ SelecTrap (AR148),’ a new drug candidate that selectively inhibits TGFβ, one of the main causative agents that suppresses the activity of immune cells in the tumor microenvironment....Another research result announcement is about 'AR092 (HLA-G/CD3 T cell engager)', one of the 'T cell bispecific antibody' pipelines."

Preclinical • Oncology